Risk factor | Significant improvement |
---|---|
Blood pressure | Blood pressure at target level: |
 | Patients without diabetes or established cardiovascular disease (CVD): < 140 mmHg systolic and < 90 mmHg diastolic. |
 | Patients with diabetes, renal disease or establish CVD: < 130 mm Hg systolic and 80 mmHg diastolic. |
 | For those who do not reach target levels: blood pressure decrease of > 10% systolic or diastolic |
Dyslipidemia | Lipid profile at target level: |
 | Primary prevention: total cholesterol (TC) < 5.0 mmol/L and low density lipoprotein (LDL) cholesterol < 3.0 mmol/l. |
 | Secondary prevention: TC < 4.0 mmol/L and LDL cholesterol < 2.5 mmol/l. |
 | For those who do not reach target levels: reduction in total cholesterol ≥ 25% or LDL ≥ 30% (whichever is greater). |
Diabetes | Fasting plasma glucose < 7.0 mmol/l |
 | Random plasma glucose of < 12 mmol/l |
Abdominal Obesity | Reduction of waist circumference to ≤ 102 cm (M), ≤ 88 cm (F) |
Left Ventricular Hypertrophy (LVH) | Regression of LVH (electrocardiogram based) according to Sokolov-Lyon criteria [44] |
Microalbuminuria | Disappearance of microalbuminuria (< 30 mg/ml in spot morning urine) |
Proteinuria | Disappearance of proteinuria (negative quantitative dipstick) |
Renal impairment | Improvement in creatinine clearance to a new estimated glomerular filtration rate class [45] after treatment. |
Smoking | Quit smoking |